251 related articles for article (PubMed ID: 32312780)
1. Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials.
Zhao L; Yan Y; Dai Q; Li X; Xu K; Zou G; Yang K; Li W; Guo X; Yang J; Li Y; Xia Q; Cao R; Zhong W
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32312780
[TBL] [Abstract][Full Text] [Related]
2. The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs.
Li Y; Huo S; Yin Z; Tian Z; Huang F; Liu P; Liu Y; Yu F
mBio; 2023 Oct; 14(5):e0127323. PubMed ID: 37610204
[TBL] [Abstract][Full Text] [Related]
3. Nitazoxanide: a first-in-class broad-spectrum antiviral agent.
Rossignol JF
Antiviral Res; 2014 Oct; 110():94-103. PubMed ID: 25108173
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
6. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
[TBL] [Abstract][Full Text] [Related]
7. [Current anti-influenza virus chemotherapy].
Yoshioka D; Tokimatsu I; Ishii H; Kadota J
Nihon Rinsho; 2010 Sep; 68(9):1679-84. PubMed ID: 20845747
[TBL] [Abstract][Full Text] [Related]
8. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection.
Esposito S; Molteni CG; Colombo C; Daleno C; Daccò V; Lackenby A; Principi N
J Clin Virol; 2010 May; 48(1):62-5. PubMed ID: 20335065
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.
Belardo G; Cenciarelli O; La Frazia S; Rossignol JF; Santoro MG
Antimicrob Agents Chemother; 2015 Feb; 59(2):1061-9. PubMed ID: 25451059
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase inhibitor resistance in influenza viruses.
Reece PA
J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
[TBL] [Abstract][Full Text] [Related]
12. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
Trebbien R; Christiansen CB; Fischer TK
J Clin Virol; 2018 May; 102():1-6. PubMed ID: 29448067
[TBL] [Abstract][Full Text] [Related]
13. Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.
Hu Y; Zhang J; Musharrafieh R; Hau R; Ma C; Wang J
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885544
[TBL] [Abstract][Full Text] [Related]
14. Antiviral resistance and the control of pandemic influenza.
Lipsitch M; Cohen T; Murray M; Levin BR
PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle.
Yang F; Pang B; Lai KK; Cheung NN; Dai J; Zhang W; Zhang J; Chan KH; Chen H; Sze KH; Zhang H; Hao Q; Yang D; Yuen KY; Kao RY
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627391
[TBL] [Abstract][Full Text] [Related]
17. Baloxavir marboxil: the new influenza drug on the market.
O'Hanlon R; Shaw ML
Curr Opin Virol; 2019 Apr; 35():14-18. PubMed ID: 30852344
[TBL] [Abstract][Full Text] [Related]
18. Drugs in development for influenza.
Boltz DA; Aldridge JR; Webster RG; Govorkova EA
Drugs; 2010 Jul; 70(11):1349-62. PubMed ID: 20614944
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
20. Influenza virus resistance to antiviral therapy.
van der Vries E; Schutten M; Fraaij P; Boucher C; Osterhaus A
Adv Pharmacol; 2013; 67():217-46. PubMed ID: 23886002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
